Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer
/PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II SBIR Contract from the...